And Eli Lilly's cloud also has a pair of silver linings that investors ... tirzepatide -- a therapy for type 2 diabetes and ...
Eli Lilly will release its third-quarter results this Wednesday. Investors are keen to see how the company has performed, ...
The company predicts the combination can help patients lose about 25% of their body weight, more than approved drugs Wegovy ...
Investing.com -- Novo Nordisk (CSE: NOVOb) has been placed on JPMorgan’s Catalyst Watch list, signaling heightened anticipation as the company approaches a pivotal moment in its development pipeline.